Two new ALTG-led trials are now open to recruitment
The ALTG has recently opened two trials that explore potential new treatments in mesothelioma and advanced NSCLC. In mesothelioma, DREAM (ALTG 15/004) is a phase 2 trial of durvalumab with first-line chemotherapy, led by Anna Nowak at Sir Charles Gairdner Hospital in WA. The NIVORAD (ALTG 14/002) study is a phase 2 placebo-controlled randomised study of nivolumab ± radiotherapy in the treatment of advanced NSCLC, led by Paul Mitchell at the Olivia Newton John Cancer Research Institute in VIC.
2nd ALTG Preceptorship in Lung Cancer cements its place
- 39 participants, including 3 from New Zealand
- 47 presentations
- 6 Preceptors – Prunella Blinman, Tom John, Chris Karapetis, Michael Millward, Ken O’Byrne and Nick Pavlakis
- Convenors – Eva Segelov, Nick Pavlakis and Peey Sei Kok (Assistant Convenor)
- 7 sponsor representatives
The Preceptorship in Lung Cancer is both an intensive learning programme for advanced trainees and junior consultants and a valuable networking opportunity through its small group format. The 1st Preceptorship was held in 2015 to great reviews from participants and organisers and the 2016 Preceptorship proved to be just as successful, cementing its place as a core educational activity in our annual calendar. The 2016 Preceptorship was made possible through educational grants provided by BI, MS, MSD, Pfizer and Roche; and representatives of each supporting company participated as observers, with similarly positive feedback on the quality of the programme. We are particularly grateful to our Conveners and Preceptors, whose contributions are vital in providing a senior perspective and mentoring role; and to the participants, for their commitment and enthusiasm in preparing and presenting their work.
The 3rd Preceptorship in Lung Cancer will be held on the 6th and 7th October, 2017. Contact Ros for more information or to register your interest.
The inaugural ALTG Lung Cancer Symposium is a success
November saw the ALTG deliver its first Lung Cancer Symposium, with the support of an educational grant provided by AstraZeneca Australia. In what will be an annual event more than 100 delegates from Australia, New Zealand and China heard presentations and discussion from an outstanding faculty.
The scientific programme focused on “hot topics” – view it here – and we are grateful to the Organising Committee and Faculty for their generosity in supporting this event with their time and contributions. A special mention goes to Lillian Leigh, a member of the ALTG’s Consumer Advisory Panel, whose opening speech set the scene through her thoughtful discussion of statistics, human connection and hope for patients with lung cancer.
We were joined by two international keynote speakers: Glenwood Goss from the Ottawa Hospital Cancer Centre and Chair of the Thoracic Oncology Site Committee of the Canadian Cancer Trials Group; and Keunchil Park, Director of the Innovative Cancer Medicine Institute at the Samsung Medical Center in Seoul.
The day before the Symposium was utilised to hold an ALTG Members’ Meeting and joint ALTG/Lung Foundation Australia “Shine A Light” dinner. “Shine A Light” is the Lung Foundation’s annual campaign, held each November, to encourage community events to raise awareness and funds for lung cancer research. This two-day format enabled delegates to make the most of their time and travel, and provided a valuable opportunity for the ALTG to hold a face-to-face meeting.
We are delighted to confirm that AstraZeneca will continue its support for the 2017 ALTG Lung Cancer Symposium, to be held on the 24th and 25th of November. Contact Ros for more information or to register your interest.